This paper examines the legal and ethical misconduct of PharmaCARE, a fictional pharmaceutical company used as a case study in business law and ethics. It identifies three major areas of violation — marketing and advertising, intellectual property, and product safety regulation — and evaluates the extent to which PharmaCARE breached applicable standards. The paper also argues against direct-to-consumer (DTC) drug marketing, analyzes how U.S. intellectual property law applied to the AD23 drug development dispute involving employee John, summarizes a real-world intellectual property theft case, assesses product liability issues stemming from patient deaths, and explores the whistleblower arguments available to John.
Business operations are deemed viable when they succeed in establishing conditions that guarantee safety for product consumers. Specified standards are applied by business entities to attain such viability. These considerations are critical in product safety, intellectual property, and marketing in general. If a company or business entity violates any of these aspects, it stands a high risk of becoming entangled in ethical and legal complications that could destroy it. PharmaCARE finds itself in such a precarious predicament owing to its blatant violation of a number of legal and ethical standards. There were both ethical and legal problems that affected its clients and business partners. Investigating corporate behavior is paramount in uncovering issues related to the legal and ethical problems of any business entity.
All business organizations need a marketing strategy in order to succeed. While some of the strategies used may be written, some businesses rely on unwritten strategic marketing plans. Embracing marketing ethics ensures that all stakeholders remain in a balanced and sustainable relationship. When ethical standards are violated by a business, it damages the relationship that exists with consumers and other important stakeholders. The pharmaceutical segment of business is even more sensitive because the products produced by companies such as PharmaCARE hold the potential to harm consumers in significant ways if ethical and legal considerations are not adhered to, both in letter and spirit. Owing to the dangers inherent in such products, international standards have been established to safeguard consumers and help such companies operate without undue complications. These standards emphasize the need to provide sufficient information about a product along with its pricing (Schlegelmilch & Oberseder, 2010). Any strategy that seeks to replace or circumvent these standards is likely to cause a backlash among consumers, as it is regarded as deceptive conduct.
PharmaCARE operated a business model that lacked any coherent legal framework. It worked in disregard of the harmful effects its drugs had on consumers, making its marketing strategy fundamentally unethical. Furthermore, the firm launched CompCARE under its name — a move that was also in complete violation of ethical and legal considerations. It overlooked the criminal aspects associated with marketing such drugs and even went so far as to bribe doctors to create fictitious patients for the new entity. All of these actions made the company's conduct entirely unethical. PharmaCARE therefore engaged in violations of marketing ethics and failed in its obligation of fair treatment of the consumer. The company was also blatantly dishonest, and its marketing efforts appeared to be aimed solely at increasing profits at the expense of consumer health and well-being.
There were also unethical behaviors in how PharmaCARE ran its advertisements. The presentation of its products was not representative of what the drugs actually did, resulting in unforeseen effects on unsuspecting consumers. This demonstrated that the company cared little about observing acceptable ethical standards in the conduct of its business (Arnold & Oakley, 2013). In addition, the company did not subject the drug to the proper legal and scientific review processes established by the relevant authorities before making it available to consumers. The advertisements were also misleading to patients who had little knowledge of the drug and lacked professional guidance.
PharmaCARE also breached intellectual property law. According to Arnold and Oakley (2013), intellectual property concerns issues of copyright, patents, and related protections. It is unethical when the rightful owner of an idea or invention is not given due recognition when a product is offered for sale or public display by another entity. Intellectual property rights are normally protected through a legal framework encompassing patent laws, trademarks, and trade secrets. In the case of PharmaCARE, the intellectual property issue can be identified in the reformulation and development of the drug AD23. This reformulation was intended to make use of AD23's gradual progression effect on Alzheimer's disease; however, there was no formal recognition or subsidiary prescription trial conducted before the drug was brought to market. Moreover, the contribution of John — the drug's original developer — was treated as inconvenient by the PharmaCARE establishment rather than being properly recognized.
The regulation of product safety was equally deficient. The company made products available for consumer use without proper inspection by the relevant authorities, meaning product safety was not guaranteed. PharmaCARE's actions contradicted established standards and rendered the drug unsafe for public use. With regard to AD23 specifically, the consequences were severe: two hundred deaths were attributed to the drug, and a heightened rate of heart attacks was observed in the affected population.
Contemporary society has given increasing credence to direct-to-consumer (DTC) marketing approaches by companies. Nevertheless, as Ventola (2011) points out, the value of these approaches is greatly undermined by the direct risks the products pose to targeted consumers, particularly when those products are pharmaceutical in nature. Issues of wrongful administration and inadequate quality controls become prominent concerns. The FDA is under pressure to cope with emerging challenges in regulating DTC approaches, because pharmaceutical companies could easily be transformed into purely commercial operations with little consideration for consumer safety and well-being.
Therefore, although proponents argue that DTC marketing helps make drugs available to consumers more easily and quickly, there are significant risks that may lead to extremely heavy costs. PharmaCARE serves as a clear case in point: the company provided misleading information about AD23 directly to consumers, the drug had circumvented proper inspection procedures, and the result was the death of 200 patients and an increased rate of heart attacks in the population. It is evident that the company shifted its focus from the well-being of the consumer to the pursuit of greater profit — a shift that produced its deeply unethical conduct.
"IP law analysis and John's compensation options"
"Liability for deaths and John's whistleblower defenses"
It is clear that PharmaCARE engaged in illegal and unethical behaviors across its marketing operations. It is especially troubling that the company continued to promote AD23 even after multiple deaths had been reported. The case demonstrates the critical importance of rigorous oversight of pharmaceutical companies and underscores the need for both robust regulatory enforcement and a strong culture of ethical accountability within the industry.
You’re 62% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.